Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Infosys Limited - Press Release

6h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INFY

0
Infosys Limited - Press Release

7h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INFY

0
INFY / Infosys Limited FORM 20-F

8h sec.gov
infy-20f_20180331.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
INFY

0
Infosys Limited - Press Release

14h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INFY

0
INFY / Infosys Limited DISCLOSURE OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION (Current Report of Foreign Issuer)

2018-07-18 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
INFY

0
Infosys Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-07-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INFY

0
Infosys Limited - Shareholders meeting

2018-07-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INFY

24
5 Asian ETFs for International S&P 500 Equivalents | InvestorPlace

2018-07-17 investorplace
Many regard the 21st century as the “Century of Asia.” As America has seen a relative decline, nations — such as China and India — growing their middle classes have placed Asia in a more influential position. Many companies within these countries have also contributed this rise. Although some trade in the U.S. as ADRs, most of these companies trade on the over-the-counter markets, if they trade at all.
500325 CHLKF HXSCF TM RELIANCE INFY NYTAB AIA KIMTY HMC EPI 0941 BABA CHL KIMTF RIGD SNE BIDU TSM RLNIY HXSCL

0
Why Infosys has lost its IT bellwether tag

2018-07-17 livemint
Bengaluru: Foreign institutional investors’ (FII) ownership of Infosys Ltd dropped to 34.87% at the end of 30 June, the lowest since March 2009, marking the souring of overseas investors’ love affair with the company.
532540 INFY TCS TTNQY

0
Infosys shares soar to all-time intraday high on June quarter earnings report

2018-07-16 livemint
Mumbai: Shares of Infosys Ltd rose as much as 5.75% on Monday to hit an all-time high of ₹1,384.40 in intraday trading, after the firm’s June quarter earnings release on Friday.
INFY

7
Infosys (INFY) Beats Q4 Earnings Estimates, Misses Revenues

2018-07-16 zacks
Infosys Limited (INFY - Free Report) reported first-quarter fiscal 2019 earnings of 27 cents per share, which topped the Zacks Consensus Estimate of 25 cents and also came ahead of the year-ago figure of 24 cents per share. Revenues of $2.83 billion increased 6.8% year over year but missed the Zacks Consensus Estimate of $2.87 billion. In terms of constant currency (CC), revenues were up 6 %. Infosys’s focus on Agile Digital and AI-driven Core services is a tailwind.
POOL VRNT GTT INFY INFY YY

0
Top technology transformation drivers for banking

2018-07-16 moneycontrol
A glance at some of the most popular services voraciously consumed today through digital channels is enough to reveal a lot.
INFY

0
Infosys shares jump over 5%; brokerages upbeat on growth prospects

2018-07-16 thehindubusinessline
Shares of India's No.2 software services exporter, Infosys Ltd, jumped as much as 5.1 per cent to Rs 1,384.40, and the brokerages are upbeat on the company’s growth prospects.
MS.PRI AUROPHARMA MS.PRK 524804 ARBQY MS.PRE INFY MS.PRF MS.PRG MS MS.PRA

2
TCS eyes $200 million in revenue from blockchain in FY19

2018-07-16 livemint
Bengaluru: Tata Consultancy Services Ltd (TCS) believes 2018-19 will be the year of blockchain adoption by the largest banks and stock exchanges, which should eventually help the Mumbai-based company generate at least $200 million in annual revenue from its blockchain practice.
WIT 532540 INFY TCS TTNQY

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to INFY / Infosys Limited on message board site Silicon Investor.

INFY: Infosys Technologies Ltd. Outsourcing and Free Trade
Infosys: First Indian Company on NASDAQ Infosys Technologies Ltd. (Nasdaq:INFY)
Indiau0027s Infosys (INFY)
CUSIP: 456788108